A5063597784- Drug-Induced Hepatotoxicity and Protection
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Pharmacogenetics and Drug Metabolism
- Drug Transport and Resistance Mechanisms
- Poisoning and overdose treatments
- Organ Transplantation Techniques and Outcomes
- Liver Diseases and Immunity
- Pharmacological Effects and Toxicity Studies
- Alcohol Consumption and Health Effects
- Hepatitis Viruses Studies and Epidemiology
- Hepatocellular Carcinoma Treatment and Prognosis
- Ultra-Wideband Communications Technology
- HIV/AIDS drug development and treatment
- Systemic Lupus Erythematosus Research
- Metabolism and Genetic Disorders
- Renal Transplantation Outcomes and Treatments
- Antenna Design and Analysis
- Drug-Induced Adverse Reactions
- Gallbladder and Bile Duct Disorders
- Liver physiology and pathology
- Pediatric Hepatobiliary Diseases and Treatments
- Traumatic Brain Injury and Neurovascular Disturbances
University of Michigan–Ann Arbor
2016-2025
Michigan Medicine
2014-2024
A. Alfred Taubman Health Care Center
2005-2024
Michigan United
2000-2024
University of Edinburgh
2024
Hepatitis B Foundation
1999-2023
Research Network (United States)
2023
American Association for the Study of Liver Diseases
2023
University of Southern California
2021
The University of Texas Southwestern Medical Center
2012-2020
Information on the stage of liver fibrosis is essential in managing chronic hepatitis C (CHC) patients. However, most models for predicting are complicated and separate formulas needed to predict significant cirrhosis. The aim our study was construct one simple model consisting routine laboratory data both cirrhosis among patients with CHC. Consecutive treatment–naive CHC who underwent biopsy over a 25–month period were divided into 2 sequential cohorts: training set (n = 192) validation...
Background: Because acute liver failure is rare, related data have been sparse. Studies suggested that viral hepatitis the most common underlying cause of this condition. Objective: To describe clinical features, presumed causes, and short-term outcomes failure. Design: Prospective cohort study. Setting: 17 tertiary care centers participating in U.S. Acute Liver Failure Study Group. Patients: 308 consecutive patients with failure, admitted over a 41-month period. Measurements: Detailed...
Severe acetaminophen hepatotoxicity frequently leads to acute liver failure (ALF). We determined the incidence, risk factors, and outcomes of acetaminophen-induced ALF at 22 tertiary care centers in United States. Detailed prospective data were gathered on 662 consecutive patients over a 6-year period fulfilling standard criteria for (coagulopathy encephalopathy), from which 275 (42%) result injury. The annual percentage acetaminophen-related rose during study 28% 1998 51% 2003. Median dose...
There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease.In this phase 2, open-label study, we assessed treatment with the NS5A inhibitor ledipasvir, nucleotide polymerase sofosbuvir, ribavirin in infected HCV genotypes 1 or 4. Cohort A enrolled cirrhosis moderate severe hepatic impairment had not undergone transplantation. B transplantation: those without cirrhosis; mild, moderate, impairment; fibrosing cholestatic...
Idiosyncratic drug-induced liver injury (DILI) is a rare adverse drug reaction and it can lead to jaundice, failure, or even death. Antimicrobials herbal dietary supplements are among the most common therapeutic classes cause DILI in Western world. diagnosis of exclusion thus careful history taking thorough work-up for competing etiologies essential its timely diagnosis. In this ACG Clinical Guideline, authors present an evidence-based approach management with special emphasis on due...
As the population that is infected with hepatitis C virus (HCV) ages, number of patients decompensated cirrhosis expected to increase.We conducted a phase 3, open-label study involving both previously treated and untreated HCV genotypes 1 through 6 who had (classified as Child-Pugh-Turcotte class B). Patients were randomly assigned in 1:1:1 ratio receive nucleotide polymerase inhibitor sofosbuvir NS5A velpatasvir once daily for 12 weeks, sofosbuvir-velpatasvir plus ribavirin or 24 weeks. The...
Developed in the early 1960s, time-domain electromagnetics, study of electromagnetic-wave propagation from a perspective, has given birth to fascinating new technology, which today is commonly referred as ultra-wideband (UWB). It now been slightly more than 25 years since 1978 seminal paper Bennett and Ross, summarized UWB's applications. thus seems appropriate, tremendous increase interest technology Federal Communications Commission modified its Part 15 rules accommodate UWB transmissions,...
Recognizing the importance of timely guidance regarding rapidly evolving field hepatitis C management, American Association for Study Liver Diseases (AASLD) and Infectious Society America (IDSA) developed a web-based process expeditious formulation dissemination evidence-based recommendations. Launched in 2014, virus (HCV) website undergoes periodic updates as necessitated by availability new therapeutic agents and/or research data. A major update was released electronically September 2017,...
Currently there is no consensus as to which staging system best in predicting the survival of patients with hepatocellular carcinoma (HCC). The aims this study were identify independent predictors and compare 7 available prognostic systems HCC. A total 239 consecutive cirrhosis HCC seen between January 1, 2000, December 31, 2003, included. Demographic, laboratory, tumor characteristics performance status determined at diagnosis before therapy. Predictors identified using Kaplan–Meir test Cox...
The increase in oral availability of felodipine and other commonly used medications when taken with grapefruit juice has been assumed to be due inhibition CYP3A4, a cytochrome P450 that is present liver intestine. To evaluate the effect repeated ingestion on CYP3A4 expression, 10 healthy men were given 8 oz three times day for 6 d. Before after receiving juice, small bowel colon mucosal biopsies obtained endoscopically, kinetics determined, activity was measured [14C N-methyl] erythromycin...
Coronavirus disease 2019 (COVID-19), the illness caused by SARS-CoV-2 virus, is rapidly spreading throughout world. Hospitals and healthcare providers are preparing for anticipated surge in critically ill patients, but few wholly equipped to manage this new disease. The goals of document provide data on what currently known about COVID-19, how it may impact hepatologists liver transplant their patients. Our aim a template development clinical recommendations policies mitigate COVID-19...
Chronic hepatitis C virus (HCV) infection with advanced cirrhosis or post-liver transplantation recurrence represents a high unmet medical need no approved therapies effective across all HCV genotypes. The open-label ALLY-1 study assessed the safety and efficacy of 60-mg once-daily dosage daclatasvir (pan-genotypic NS5A inhibitor) in combination sofosbuvir at 400 mg once daily (NS5B ribavirin 600 mg/day for 12 weeks 24-week follow-up two cohorts patients chronic any genotype either...
Objective: To provide a uniform platform from which to study acute liver failure, the U.S. Acute Liver Failure Study Group has sought standardize management of patients with failure within participating centers. Methods: In areas where consensus could not be reached because divergent practices and paucity studies in patients, additional information was gleaned intensive care literature on intracranial hypertension non-acute patients. Experts diverse fields were included development standard...
The incidence of hepatocellular carcinoma (HCC) in the United States is increasing, but clinical characteristics American patients with HCC have not been well described. aims this study were to determine etiology liver disease and short-term outcome among presenting a single center States. One hundred five consecutive studied; mean age was 59 years, 67% men, 76% non-Hispanic white. most common hepatitis C (51%) cryptogenic cirrhosis (29%). Half had histologic or features associated...
Mortality due to hepatocellular carcinoma (HCC) has not improved over the last 20 years. This is in part poor performance of available tumor markers leading delays diagnosis. Des–gamma carboxy–prothrombin (DCP) been reported be more sensitive and specific for diagnosis HCC Japanese patients compared with α–fetoprotein (AFP). We conducted a cross–sectional case control study evaluate whether DCP than AFP differentiating from nonmalignant liver disease cohort American single referral center....
The Drug-Induced Liver Injury Network (DILIN) studies hepatotoxicity caused by conventional medications as well herbals and dietary supplements (HDS). To characterize its outcomes from HDS versus medications, patients with attributed to or were enrolled prospectively between 2004 2013. study took place among eight U.S. referral centers that are part of the DILIN. Consecutive liver injury referred a DILIN center eligible. final sample comprised 130 (15.5%) all subjects (839) who judged have...
Drug-induced liver injury (DILI) is considered to be a diagnosis of exclusion. Liver biopsy may contribute diagnostic accuracy, but the histological features DILI and their relationship biochemical parameters outcomes are not well defined. We have classified pathological pattern systematically evaluated changes in biopsies obtained from 249 patients with suspected enrolled prospective, observational study conducted by Drug Induced Injury Network. Histological were analyzed for frequency...
The incidence and risk factors for adefovir-resistant HBV have not been clearly defined.To characterize the virologic response to adefovir, determine rate of adefovir resistance explore associated with initial (IVR) resistance.All hepatitis B patients who received > or =6 months at our center were prospectively monitored resistance.Forty three included; mean treatment duration was 18 (range 6-45). Thirty four (79%) had prior lamivudine. IVR observed in 44% higher pretreatment ALT (P = 0.05)...